Stay Informed on Corporate Sustainability

Author: Jed Nykolle Harme

A compelling optimism has surfaced across the global pharmaceutical and life science industry.

Author: Pharmaceutical Manufacturer

Rotzinger PharmaPack is launching a new filling and capping platform for over-the-counter (OTC) products such as non-aseptic pharmaceuticals as well as solid and liquid products from the cosmetics, personal care, and nutraceutical industries.

Author: NBC

Trump's demand to make the data public comes amid escalating divisions between the Centers for Disease Control and Prevention and HHS Secretary Robert F. Kennedy Jr.

Author: Contract Pharma

eXmoor Pharma, a UK-based contract development and manufacturing organization (CDMO) specializing in cell and gene therapies, has entered a strategic partnership with Anthony Nolan Cell Therapy & Laboratory Services (CT&LS), a leader in cellular starting materials, to provide an integrated solution for cell therapy developers.

Author: Contract Pharma

Accro Bioscience, a biotechnology company, has entered into an agreement granting Fosun Pharma exclusive rights to develop, manufacture, and commercialize its TYK2/JAK1 inhibitor, AC-201, in Greater China, encompassing Chinese Mainland, Hong Kong SAR, and Macau SAR. Accro will retain global rights for AC-201 outside these regions.

Author: EURACTIV

The US is losing patience with the EU on digital policy and its Ukraine long game; Ireland’s pharma negotiations could be hostage to a wider standoff

Author: Yahoo Finance

India plans to increase pharmaceutical exports to Russia, the Netherlands and Brazil, according to two industry sources aware of the matter, aiming to expand its presence beyond the United States, its largest market, amid tariff-related concerns.

Author: Pharmaphorum

Regeneron could be just a few months away from filing for approval of a therapy for the neuromuscular disorder generalised myasthenia gravis (gMG), cemdisiran, which can be dosed just four times a year.

Author: Jed Nykolle Harme

The pharmaceutical and life sciences sector continues to navigate an era defined by innovation, scrutiny, and the recalibration of trust.

Author: Fierce Pharma

A new treatment option for certain patients with blood cancers has passed muster with the European Commission (EC).